DFTX
Definium Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Definium Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
No other changes.
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Definium Therapeutics, Inc.
33.36
+0.89 · +2.75%
post 33.41 +0.14%
Same SIC code · 6
Same SEC industry code: Usana Health Sciences Inc, Niagen Bioscience, Inc., MediWound Ltd. and 3 more; of Definium Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Usana Health Sciences Inc, Niagen Bioscience, Inc., MediWound Ltd. and 3 more; of Definium Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Tall tick = annual report · Source: EDGAR
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $528.4M | 9.39% | +32.46% |
| venBio Select Advisor | $338.2M | 6.01% | +43.78% |
| Driehaus | $322.0M | 5.72% | +15.79% |
| Jupiter Topco | $264.0M | 4.69% | — |
| Capital World Investors | $252.5M | 4.49% | new |
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $528.4M | 9.39% | +32.46% |
| venBio Select Advisor | $338.2M | 6.01% | +43.78% |
| Driehaus | $322.0M | 5.72% | +15.79% |
| Jupiter Topco | $264.0M | 4.69% | — |
| Capital World Investors | $252.5M | 4.49% | new |
Bull2
Bear1
Expected move
Inputsspot 33.42exp Nov 20ATM strike 33ATM straddle 4.92IV 86%